The therapeutic activity of ifosfamide in urologic tumors has been reviewed. Ifosfamide has definite activity in nephroblastoma, where it represents the treatment of choice for children who are not cured by front-line chemotherapy, and for the adults who are diagnosed with this uncommon disease. Definite therapeutic activity has also been shown in patients with urothelial tract malignancies and it represents a major option for patients failing first-line cisplatin-based chemotherapy. However, promising results have been achieved in chemo-naïve patients in combination with taxanes or gemcitabine, though at the price of relevant toxicity. A modest activity has been shown by ifosfamide in renal cancer (including the sarcomatoid variant) and in hormone-refractory prostate cancer, which unfortunately respond poorly to cytotoxic chemotherapy. No results of ifosfamide in penile carcinoma are available so far.

Keywords:
Ifosfamide, Urologic cancer
1.
Overmoyer BA: Ifosfamide in the treatment of breast cancer. Semin Oncol 1996;23(suppl 6):38–41.
2.
Sarosy G: Ifosfamide-pharmacologic overview. Semin Oncol 1989;16(suppl 3):2–8.
3.
Hortobagyi GN: Activity of ifosfamide in breast cancer. Semin Oncol 1992;19(suppl 12):36–41.
4.
Roth BJ: Chemotherapy for advanced bladder cancer. Semin Oncol 1996;23:633–644.
5.
Skinner R: Strategies to prevent nephrotoxicity of anticancer drugs. Curr Opin Oncol 1995;7:310–315.
6.
Gad-el-Mawla N, Hamza MR, Zikri ZK, el-Serafi M, el-Khodary A, Khaled H, Abdel-Wareth A: Chemotherapy in invasive carcinoma of the bladder. A review of phase II trials in Egypt. Acta Oncol 1989;28:73–76.
7.
Ohtaguro K, Ueda K, Niijma T et al: Clinical evaluation of Z4942 (ifosfamide) for malignant urological tumors. Acta Urol Jpn 1981;27:459.
8.
Witte RS, Elson P, Bono B, Knop R, Richardson RR, Dreicer R, Loehrer PJ Sr: Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. J Clin Oncol 1997;15:589–593.
9.
Pronzato P, Vigani A, Pensa F, Vanoli M, Tani F, Vaira F: Second-line chemotherapy with ifosfamide as outpatient treatment for advanced bladder cancer. Am J Clin Oncol 1997;20:519–521.
10.
Kyriakakis Z, Dimopoulos MA, Kostakopoulos A, Karayiannis A, Sofras F, Zervas A, Giannopoulos A, Dimopoulos C: Cisplatin, ifosfamide, methotrexate and vinblastine combination chemotherapy for metastatic urothelial cancer. J Urol 1997;158:408–411.
11.
Müller M, Heicappell R, Steiner U, Goessl C, Miller K: Side effects of chemotherapy for advanced urothelial carcinoma with etoposide and ifosfamide. Urol Int 1997;59:248–251.
12.
Schmidt AS, Rüther U, Eisenberger F: First-line therapy with ifosfamide and etoposide for the treatment of advanced bladder cancer. J Urol 1993;149:318, abstr 421.
13.
Raghavan D: Advanced bladder and urothelial cancers. Eur J Cancer 2000;36(suppl 2):1–6.
14.
Calabrò F, Sternberg CN: New drugs and new approaches for the treatment of metastatic urothelial cancer. World J Urol 2002;20:158–166.
15.
Fukui I, Yonese J, Tsukamoto T, Yoshida T, Kim T, Tohma T, Ishiwata D: Combination chemotherapy with ifosfamide, 5-fluorouracil, etoposide and cisplatin for metastatic urothelial cancer. Cancer Chemother Pharmacol 2001;48:88–93.
16.
Einhorn LH, Roth BJ, Ansari R, Dreicer R, Gonin R, Loehrer PJ: Phase II trial of vinblastine, ifosfamide and gallium combination chemotherapy in metastatic urothelial carcinoma. J Clin Oncol 1994;12:2271–2276.
17.
Sweeney CJ, Williams SD, Finch DE, Bihrle R, Foster RS, Collins M, Fox S, Roth BJ: A phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium. Cancer 1999;86:514–518.
18.
Krege S, Rembrink V, Borgermann C, Otto T, Rubben H: Docetaxel and ifosfamide as second-line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: A phase 2 study. J Urol 2001;165:67–71.
19.
Bajorin DF, McCaffrey JA, Dodd PM, Hilton S, Mazumdar M, Kelly WK, Herr H, Scher HI, Icasiano E, Higgins G: Ifosfamide, paclitaxel and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: Final report of a phase II trial evaluating two dosing schedules. Cancer 2000;88:1671–1678.
20.
Dodd PM, McCaffrey JA, Hilton S, Mazumdar M, Herr H, Kelly WK, Icasiano E, Boyle MG, Bajorin DF: Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract. J Clin Oncol 2000;18:840–846.
21.
Bajorin DF: Exploring sequenced chemotherapy regimens in the treatment of transitional cell carcinoma of the urothelial tract. Eur J Cancer 2000;36(suppl 2):26–29.
22.
Millikan RE, Plunkett WK, Smith TL, Williams DL, Logothetis CJ: Gemcitabine modulation of alkylator therapy. Cancer 2001;92:194–199.
23.
Pagliaro LC, Millikan RE, Tu SM, Williams D, Daliani D, Papandreou CN, Logothetis CJ: Cisplatin, gemcitabine and ifosfamide as weekly therapy: A feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma. J Clin Oncol 2002;20:2965–2970.
24.
Millikan RE: Chemotherapy of advanced prostatic carcinoma. Semin Oncol 1999;26:185–191.
25.
Beer T, Raghavan D: Chemotherapy for hormone-refractory prostate cancer: Beauty is in the eye of the eye of the beholder. Prostate 2000;45:184–193.
26.
Petrylak D, Shelton G, England-Owen C, Pfaff C, Bagliella E, Diuleo R, Katz A, Zuech N, Sawczuk I, Benson M, Olsson C: Response and preliminary survival results of a phase II study of docetaxel + estramustine in patients with androgen-independent prostate cancer. Proc Am Soc Clin Oncol 2000;19:334, abstr 1312.
27.
Savarese D, Taplin ME, Halabi S, Hars V, Kreis W, Vogelzang N: A phase II study of docetaxel (taxotere), estramustine and low-dose hydrocortisone in men with hormone-refractory prostate cancer: Preliminary results of Cancer and Leukemia Group B Trial 9780. Semin Oncol 1999;26(suppl 17):39–44.
28.
Mahjoubi M, Azab M, Ghosn M, Theodore C, Droz JP: Phase II trial of ifosfamide in the treatment of metastatic hormone-refractory patients with prostatic cancer. Cancer Invest 1990;8:477–481.
29.
Yagoda A: Chemotherapy for advanced renal-cell carcinoma: 1983–1993. Semin Oncol 1995;22:42–60.
30.
Chao D, Zisman A, Freedland S, Pantuck AJ, Said JW, Belldegrun AS: Sarcomatoid renal cell carcinoma: Basic biology, clinical behavior and response to therapy. Urol Oncol 2001;6:281.
31.
Mian BM, Bhadkamkar N, Slaton JW, Pisters PW, Daliani D, Swanson DA, Pisters LL: Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma. J Urol 2002;167:65–70.
32.
Bangalore N, Bhargava P, Hawkins MJ, Bhargava P: Sustained response of sarcomatoid renal-cell carcinoma to MAID chemotherapy: Case report and review of the literature. Ann Oncol 2001;12:271–274.
33.
Yalcin S, Barista I, Tekuzman G, Gullu I: Dramatic response to ifosfamide, mesna and doxorubicine chemotherapy regimen in an adult with clear cell sarcoma of the kidney. J Urol 1995;155:2024.
34.
Escudier B, Droz JP, Rolland F, Terrier-Lacombe MJ, Gravis G, Beuzeboc P, Chauvet B, Chevreau C, Eymard JC, Lesimple T, Merrouche Y, Oudard S, Priou F, Guillemare C, Gourgou S, Culine S: Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: A phase II study of the genitourinary group of the French Federation of Cancer Centers. J Urol 2002;168:959–961.
35.
Cairo MS: The use of ifosfamide, carboplatin and etoposide in children with solid tumors. Semin Oncol 1995;22(suppl 7):23–27.
36.
Gururangan S, Bowman LC, Parham DM, Wilimas JA, Rao B, Pratt CB, Douglass EC: Primary extracranial rhabdoid tumors. Cancer 1993;71:2653–2659.
37.
Bozeman G, Bissada NK, Abboud MR, Laver J: Adult Wilms’ tumor: Prognostic and management considerations. Urology 1995;45:1055–1058.
38.
Orditura M, De Vita F, Catalano G: Adult Wilms’ tumor: A case report. Cancer 1997;80:1961–1965.
39.
Connell CF, Berger NA: Management of advanced squamous cell carcinoma of the penis. Urol Clin North Am 1994;21:745–756.
40.
Zanetta G, Fei F, Mangioni C: Chemotherapy with paclitaxel, ifosfamide and cisplatin for the treatment of squamous cell cervical cancer: The experience of Monza. Semin Oncol 2000;27(suppl 1):23–27.
© 2003 S. Karger AG, Basel
2003
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.